GlaxoSmithKline (GSK) has signed an agreement to reserve, produce, and supply its influenza vaccine Adjupanrix to 12 European countries.
Under the terms of the deal, GSK has signed a contract with the European Commission’s (EC) Health Emergency Preparedness and Response Authority (HERA), for the reservation of future manufacture of 85 million doses of Adjupanrix (split virion, inactivated, adjuvanted).
{iframe}https://bioprocessintl.com/bioprocess-insider/deal-making/pandemic-preparedness-gsk-enters-agreement-with-12-eu-countries/{/iframe}